Raich P C, Walker B K, Rogers J S, Subramanian V P, Fontana J A, Knost J A, Denning B
Cancer Treat Rep. 1983 May;67(5):485-7.
Nineteen patients with advanced refractory lymphoma and 12 patients with acute leukemia, including seven in blastic crisis of chronic myelogenous leukemia (CML), were treated with vindesine in combination with prednisone. Of 16 evaluable patients with lymphocytic or histiocytic lymphoma, one achieved complete remission (6%) and eight achieved partial remissions (50%). Median duration of response was 12 weeks (range, 4-72+). Four of six evaluable patients in blastic crisis of CML showed definite improvement in blood cell counts and symptoms. The major dose-limiting toxic effect was bone marrow suppression, while neurotoxicity was seldom cause for dose modification. The study shows vindesine and prednisone to be active in heavily pretreated patients with non-Hodgkin's lymphoma and blastic phase of CML.
19例晚期难治性淋巴瘤患者和12例急性白血病患者，包括7例慢性粒细胞白血病（CML）急变期患者，接受了长春地辛联合泼尼松治疗。在16例可评估的淋巴细胞性或组织细胞性淋巴瘤患者中，1例获得完全缓解（6%），8例获得部分缓解（50%）。缓解的中位持续时间为12周（范围4 - 72 +周）。6例可评估的CML急变期患者中有4例血细胞计数和症状有明显改善。主要的剂量限制性毒性作用是骨髓抑制，而神经毒性很少导致剂量调整。该研究表明长春地辛和泼尼松对经过大量预处理的非霍奇金淋巴瘤和CML急变期患者有效。
